Cost of Revenue Comparison: Galapagos NV vs Xencor, Inc.

Cost of Revenue: A Tale of Two Biotech Companies

In the competitive world of biotechnology, Galapagos NV and Xencor, Inc. have shown contrasting trajectories in their cost of revenue over the past decade. From 2014 to 2023, Galapagos NV experienced a dramatic rise, peaking in 2020 with a cost of revenue nearly 370% higher than in 2014. However, post-2020, the company saw a significant drop, with costs plummeting to just 3% of their peak by 2021. In contrast, Xencor, Inc. displayed a more consistent upward trend, culminating in a 2023 cost of revenue that was over 13 times higher than its 2014 figure. This divergence highlights the dynamic nature of the biotech industry, where strategic decisions and market conditions can lead to vastly different financial outcomes. As investors and analysts look to the future, understanding these trends is crucial for making informed decisions.